Sept 30 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES TOPLINE RESULTS IN BETONMACE PHASE 3 EPIGENETICS TRIAL
* RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT
* RESVERLOGIX CORP - BETONMACE DID NOT MEET PRIMARY ENDPOINT
* RESVERLOGIX CORP - FULL STUDY RESULTS WILL BE PRESENTED DURING A LATE-BREAKING SCIENCE SESSION AT AHA 2019
* RESVERLOGIX CORP - APABETALONE DEMONSTRATED TOLERABILITY AND SAFETY
* RESVERLOGIX CORP - APABETALONE DEVELOPMENT TO CONTINUE TO BE ADVANCED BY COMPANY BASED ON BETONMACE RESULTS